Fas Ligand Delivery by a Prostate-Restricted Replicative Adenovirus Enhances Safety and Antitumor Efficacy
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-07-0342
Full Text
Open PDFAbstract
Available in full text
Date
September 15, 2007
Authors
Publisher
American Association for Cancer Research (AACR)